Amneal Pharmaceuticals, Inc. Class A Common Stock
AMRXAmneal Pharmaceuticals, Inc. Class A (AMRX) is a pharmaceutical company that develops, manufacturers, and distributes generic and specialty medications. Founded in 2013, it focuses on providing affordable healthcare solutions across various therapeutic areas, including CNS, dermatology, and gastrointestinal treatments. The company operates through a diverse portfolio of products and emphasizes innovation, quality, and accessibility in its offerings.
Company News
Amneal Pharmaceuticals received FDA approval for additional strengths and vial presentations of iohexol injection (350 mg iodine/mL and 300 mg iodine/mL), with planned Q3 2026 launch. The expanded portfolio is expected to address the majority of U.S. iohexol injection market demand, which generated approximately $706 million in annual sales as of...
DelveInsight's report analyzes the IgE receptor antagonists pipeline with 12+ companies developing therapies for allergic diseases. ADL-018 by Amneal/Kashiv leads in registration stage, while LP-003 by LongBio shows superior Phase II efficacy compared to omalizumab. The market is becoming increasingly competitive with focus on clinical differenti...
Amneal Pharmaceuticals (AMRX) shares rose 3.76% in premarket trading after announcing a definitive agreement to acquire Kashiv BioSciences for $1.1 billion. The acquisition aims to establish Amneal as a fully integrated global biosimilar platform, positioning it to capitalize on a projected $300 billion global biologics loss-of-exclusivity opport...
Amneal Pharmaceuticals announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol on April 14, 2026. These are the company's first two metered-dose inhalation (MDI) product launches, marking entry into the complex inhalation category. The products target large markets worth approximate...
The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity...
